10-Q/A: Range Impact Inc. Files Amended Quarterly Report After SEC Inquiry on Mining Disclosures

Range Impact Inc. has filed an amended quarterly report to include mine safety disclosures after the SEC questioned the company's ongoing mining activities.

Summary

• Range Impact Inc. filed an amendment to its Form 10-Q for the quarter ended March 31, 2024, to include mine safety disclosures as required by the SEC.
• The amendment was prompted by an SEC letter stating that the company's Form 10-Q for the period ended June 30, 2024, indicated ongoing mining activities.
• The company's financial statements for the quarter ended March 31, 2024, were restated due to an expense being incorrectly posted to April instead of March.
• The restatement resulted in a net loss of $1,213,840 for the quarter, compared to a previously reported loss of $751,149.
• Revenue for the quarter was $3,909,893, with a gross profit of $18,854, impacted by increased depreciation.
• The company operates six business segments: Range Reclaim, Range Minerals, Range Water, Range Security, Range Land, and Graphium Biosciences.
• The company's largest customer accounted for 67% of total sales for the quarter and 89% of accounts receivable.
• The company had a working capital of $28,754 as of March 31, 2024.
• The company is pursuing a capital raise for its Graphium Biosciences drug development program, estimated at $20 million.
• The company's internal controls over financial reporting were deemed ineffective due to a material weakness related to expense recording and accruals.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including a restatement, a substantial net loss, low working capital, and a material weakness in internal controls. While there are some positive aspects, such as revenue growth and a diverse business model, the overall sentiment is negative due to the financial and operational risks.

Positives

• Revenue increased by $895,006 compared to the same quarter last year, driven by new business in the Range Reclaim segment.
• The company is actively pursuing a capital raise for its Graphium Biosciences drug development program.
• The company has a diverse range of operating segments focused on environmental solutions and drug development.
• The company is expanding its market share with existing customers and adding new customers.
• The company is developing innovative solutions for water treatment and sustainable agriculture through its Range Water segment.

Negatives

• The company reported a net loss of $1,213,840 for the quarter ended March 31, 2024.
• Gross profit was significantly impacted by increased depreciation on equipment acquired in August 2023.
• The company has a high concentration of credit risk with its largest customer.
• The company's working capital is very low at $28,754 as of March 31, 2024.
• A material weakness was identified in the company's internal controls over financial reporting.
• The company's internal controls over financial reporting were deemed ineffective.

Risks

• The company's financial results are heavily reliant on a single major customer, creating a significant concentration risk.
• The company's low working capital balance could pose challenges to its operations.
• The material weakness in internal controls over financial reporting could lead to future financial misstatements.
• The company's ability to raise the necessary capital for its drug development program is uncertain.
• The company faces competition from larger and better-capitalized businesses.
• The company's operations are subject to regulatory risks, particularly in the mining and drug development sectors.

Future Outlook

The company expects its operating businesses to generate operating income and positive cash flow over the 12 months following March 31, 2024, and is exploring financing options to accelerate its growth strategy.

Management Comments

• The company strives to instill a corporate culture of honesty, integrity and respect while advancing our mission of doing well by doing good.
• The company believes that doing well and doing good are not mutually exclusive, and that an impact investing strategy can balance the environmental, social and economic needs of people and the planet while also generating attractive risk-adjusted financial returns for shareholders.
• The company is planning for continued growth in its land reclamation, water restoration and consulting businesses by expanding its market share with existing coal mining customers and reclamation bond insurers, adding new coal mining and non-coal mining customers, and collaborating with the Company’s other operating businesses to generate incremental sales opportunities.

Industry Context

The company operates in the impact investing space, focusing on environmental solutions and drug development, which are areas of increasing investor interest. The company's focus on the Appalachian region aligns with the need for economic development and environmental remediation in that area. The company's drug development program targets the inflammatory bowel disease market, which is a significant and growing market.

Comparison to Industry Standards

• The company's gross profit margin of approximately 0.5% is significantly below industry standards for environmental services and construction companies, which typically range from 15% to 30%.
• The company's reliance on a single major customer for 67% of its revenue is a significant risk, as most companies aim for a more diversified customer base.
• The company's working capital of $28,754 is extremely low compared to industry benchmarks, which typically require a healthy working capital to cover operational expenses and short-term liabilities.
• The company's net loss of $1,213,840 for the quarter is concerning, as most companies aim for profitability or at least a path to profitability.
• The company's internal control weaknesses are a significant concern, as most public companies are expected to have robust internal controls to ensure accurate financial reporting.
• Compared to companies like Tetra Tech or AECOM, which are established players in environmental services, Range Impact is a much smaller company with a limited track record.
• The company's drug development program is in an early stage compared to established pharmaceutical companies, and faces significant regulatory and financial hurdles.

Stakeholder Impact

• Shareholders may be concerned about the company's financial performance and the material weakness in internal controls.
• Employees may be affected by the company's financial challenges and potential restructuring.
• Customers may be impacted by the company's ability to deliver services and products.
• Suppliers may be affected by the company's financial challenges and potential payment delays.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company plans to remediate the material weakness in its internal controls over financial reporting.
• The company will continue to pursue its capital raise for the Graphium Biosciences drug development program.
• The company will focus on expanding its market share and adding new customers in its operating segments.
• The company will continue to develop innovative solutions for water treatment and sustainable agriculture.

Key Dates

Keywords

mine safety, environmental services, land reclamation, water restoration, cannabinoid prodrugs, impact investing, biochar, mining, financial restatement, internal controls